Opus Genetics (IRD) Other Non-Current Assets (2010 - 2026)
Opus Genetics (IRD) posted quarterly Other Non-Current Assets of $25681.0 for Q3 2020, little changed year-over-year from $25681.0 in Q4 2019, and little changed quarter-over-quarter from $25681.0 in Q2 2020.
Opus Genetics (IRD) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Opus Genetics (IRD) has reported Other Non-Current Assets for 11 consecutive years, with $25681.0 the latest figure, recorded in Q3 2020.
- In Q3 2020, Other Non-Current Assets changed 0.0% year-over-year to $25681.0; the TTM figure through Sep 2020 stood at $25681.0 (changed 0.0% YoY), while the FY2019 annual figure was $25681.0, down 16.58% from the prior year.
- Other Non-Current Assets held at $25681.0 in Q3 2020 per IRD's latest filing, from $25681.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $30785.0 in Q1 2016 and bottomed at $25681.0 in Q2 2019.
- Historically, Other Non-Current Assets has averaged $29173.2 across 5 years, with a median of $30785.0 in 2016.
- Annual changes were most pronounced in 2016 — Other Non-Current Assets gained 19.87% — and 2019, when it dropped 16.58%.
- Opus Genetics' Other Non-Current Assets stood at $30785.0 in 2016, then changed by 0.0% to $30785.0 in 2017, then changed by 0.0% to $30785.0 in 2018, then retreated by 16.58% to $25681.0 in 2019, then changed by 0.0% to $25681.0 in 2020.
- Business Quant data shows IRD's Other Non-Current Assets at $25681.0 in Q3 2020, $25681.0 in Q2 2020, and $25681.0 in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Opus Genetics | 298.36 Mn | 209.55 Mn | - | 100,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 100,000.00 |
| Sep 30, 2020 | 25,681.00 |
| Jun 30, 2020 | 25,681.00 |
| Mar 31, 2020 | 25,681.00 |
| Dec 31, 2019 | 25,681.00 |
| Sep 30, 2019 | 25,681.00 |
| Jun 30, 2019 | 25,681.00 |
| Mar 31, 2019 | 30,785.00 |
| Dec 31, 2018 | 30,785.00 |
| Sep 30, 2018 | 30,785.00 |
| Jun 30, 2018 | 30,785.00 |
| Mar 31, 2018 | 30,785.00 |
| Dec 31, 2017 | 30,785.00 |
| Sep 30, 2017 | 30,785.00 |
| Jun 30, 2017 | 30,785.00 |
| Mar 31, 2017 | 30,785.00 |
| Dec 31, 2016 | 30,785.00 |
| Sep 30, 2016 | 30,785.00 |
| Jun 30, 2016 | 30,785.00 |
| Mar 31, 2016 | 30,785.00 |